Eli Lilly Share Holder Equity 1986-2025 | LLY

Eli Lilly share holder equity from 1986 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
  • Eli Lilly share holder equity for the quarter ending June 30, 2025 was $18.349B, a 34.57% increase year-over-year.
  • Eli Lilly share holder equity for 2024 was $14.272B, a 31.37% increase from 2023.
  • Eli Lilly share holder equity for 2023 was $10.864B, a 0.82% increase from 2022.
  • Eli Lilly share holder equity for 2022 was $10.775B, a 17.7% increase from 2021.
Eli Lilly Annual Share Holder Equity
(Millions of US $)
2024 $14,272
2023 $10,864
2022 $10,775
2021 $9,155
2020 $5,825
2019 $2,699
2018 $10,909
2017 $11,668
2016 $14,081
2015 $14,590
2014 $15,388
2013 $17,641
2012 $14,774
2011 $13,536
2010 $12,413
2009 $9,525
2008 $6,738
2007 $13,504
2006 $10,981
2005 $10,792
2004 $10,920
2003 $9,765
2002 $8,274
2001 $7,104
2000 $6,047
1999 $5,013
1998 $4,430
1997 $4,646
1996 $6,100
1995 $5,433
1994 $5,356
1993 $4,569
1992 $4,892
1991 $4,966
1990 $3,468
1989 $3,757
1988 $3,225
1987 $3,043
1986 $2,740
1985 $2,388
Eli Lilly Quarterly Share Holder Equity
(Millions of US $)
2025-06-30 $18,349
2025-03-31 $15,847
2024-12-31 $14,272
2024-09-30 $14,321
2024-06-30 $13,636
2024-03-31 $12,897
2023-12-31 $10,864
2023-09-30 $11,307
2023-06-30 $11,149
2023-03-31 $11,295
2022-12-31 $10,775
2022-09-30 $10,166
2022-06-30 $8,659
2022-03-31 $9,462
2021-12-31 $9,155
2021-09-30 $7,954
2021-06-30 $6,664
2021-03-31 $7,099
2020-12-31 $5,825
2020-09-30 $4,996
2020-06-30 $4,272
2020-03-31 $3,197
2019-12-31 $2,699
2019-09-30 $3,462
2019-06-30 $2,857
2019-03-31 $2,565
2018-12-31 $10,909
2018-09-30 $14,151
2018-06-30 $11,621
2018-03-31 $14,588
2017-12-31 $11,668
2017-09-30 $14,961
2017-06-30 $14,170
2017-03-31 $14,104
2016-12-31 $14,081
2016-09-30 $15,616
2016-06-30 $14,656
2016-03-31 $15,029
2015-12-31 $14,590
2015-09-30 $15,241
2015-06-30 $14,705
2015-03-31 $14,947
2014-12-31 $15,388
2014-09-30 $17,683
2014-06-30 $17,995
2014-03-31 $18,349
2013-12-31 $17,641
2013-09-30 $16,896
2013-06-30 $15,236
2013-03-31 $14,956
2012-12-31 $14,774
2012-09-30 $16,057
2012-06-30 $14,308
2012-03-31 $14,823
2011-12-31 $13,536
2011-09-30 $15,058
2011-06-30 $14,277
2011-03-31 $13,934
2010-12-31 $12,413
2010-09-30 $12,406
2010-06-30 $10,235
2010-03-31 $10,462
2009-12-31 $9,525
2009-09-30 $9,905
2009-06-30 $8,560
2009-03-31 $7,725
2008-12-31 $6,738
2008-09-30 $13,742
2008-06-30 $14,738
2008-03-31 $14,910
2007-12-31 $13,504
2007-09-30 $12,947
2007-06-30 $11,560
2007-03-31 $11,534
2006-12-31 $10,981
2006-09-30 $13,055
2006-06-30 $11,929
2006-03-31 $11,694
2005-12-31 $10,792
2005-09-30 $11,383
2005-06-30 $10,269
2005-03-31 $11,598
2004-12-31 $10,920
2004-09-30 $11,310
2004-06-30 $10,499
2004-03-31 $10,559
2003-12-31 $9,765
2003-09-30 $9,485
2003-06-30 $8,686
2003-03-31 $8,728
2002-12-31 $8,274
2002-09-30 $8,262
2002-06-30 $7,747
2002-03-31 $7,700
2001-12-31 $7,104
2001-09-30 $7,367
2001-06-30 $6,763
2001-03-31 $6,594
2000-12-31 $6,047
2000-09-30 $6,064
2000-06-30 $5,514
2000-03-31 $5,658
1999-12-31 $5,013
1999-09-30 $4,867
1999-06-30 $4,451
1999-03-31 $4,860
1998-12-31 $4,430
1998-09-30 $4,509
1998-06-30 $4,642
1998-03-31 $4,793
1997-12-31 $4,646
1997-09-30 $4,391
1997-06-30 $4,670
1997-03-31 $6,570
1996-12-31 $6,100
1996-09-30 $6,027
1996-06-30 $5,894
1996-03-31 $5,846
1995-12-31 $5,433
1995-09-30 $5,486
1995-06-30 $5,974
1995-03-31 $5,835
1994-12-31 $5,356
1994-09-30 $5,315
1994-06-30 $5,149
1994-03-31 $4,941
1993-12-31 $4,569
1993-09-30 $5,471
1993-06-30 $5,355
1993-03-31 $5,221
1992-12-31 $4,892
1992-09-30 $5,003
1992-06-30 $5,554
1992-03-31 $5,307
1991-12-31 $4,966
1991-09-30 $4,861
1991-06-30 $4,860
1991-03-31 $4,686
1990-12-31 $3,468
1990-09-30 $3,463
1990-06-30 $3,894
1990-03-31 $4,105
1989-12-31 $3,757
1989-09-30 $3,677
1989-06-30 $3,554
1989-03-31 $3,433
1988-12-31 $3,225
1988-09-30 $3,235
1988-06-30 $3,177
1988-03-31 $3,207
1987-12-31 $3,043
1987-09-30 $3,012
1987-06-30 $2,951
1987-03-31 $2,963
1986-12-31 $2,740
1985-12-31 $2,388
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12